Using estimates from the Cox proportional hazards model limited to the patients who completed all 120 weeks of continuation therapy, Kaplan-Meier curves were projected for each TPMT phenotypic group and for each treatment arm (conventional v targeted) at each of two cumulative 6MP dose intensities (70% v 85% of possible 6MP dosages). The curves projected for those with wild-type TPMT phenotype are depicted in the left panel, and those with either heterozygous or mutant TPMT phenotype are depicted in the right panel.